Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
44 studies found for:    "Microscopic polyangiitis"
Show Display Options
Rank Status Study
21 Completed Vasculitis Illness Perception (VIP) Study
Conditions: Wegener Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu's Arteritis;   Henoch-Schoenlein Purpura;   Behcet's Disease;   CNS Vasculitis
Intervention:
22 Completed Reproductive Health in Men and Women With Vasculitis
Conditions: Giant Cell Arteritis;   Takayasu's Arteritis;   Polyarteritis Nodosa;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Behcet's Disease;   Kawasaki Disease;   Henoch-schoenlein Purpura;   Vasculitis, Central Nervous System;   Drug-induced Necrotizing Vasculitis
Intervention:
23 Recruiting Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Interventions: Drug: Glucocorticoids;   Drug: Rituximab
24 Enrolling by invitation Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Intervention: Other: Observational
25 Terminated Plasma Exchange for Renal Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis
Interventions: Procedure: Plasma exchange;   Drug: Intravenous methyl prednisolone;   Drug: Methyl prednisolone
26 Unknown  Alemtuzumab for ANCA Associated Refractory Vasculitis
Conditions: Vasculitis;   Microscopic Polyangiitis;   Granulomatosis With Polyangiitis;   Wegener's
Intervention: Drug: Alemtuzumab
27 Recruiting One-Time DNA Study for Vasculitis
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss);   Giant Cell Arteritis;   Granulomatosis With Polyangiitis (Wegener's);   Microscopic Polyangiitis;   Polyarteritis Nodosa;   Takayasu's Arteritis
Intervention:
28 Recruiting American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis
Conditions: Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg Strauss Syndrome;   Polyarteritis Nodosa;   Giant Cell Arteritis;   Takayasu Arteritis
Intervention:
29 Completed Anti-Cytokine Therapy for Vasculitis
Conditions: Wegener's Granulomatosis;   Renal Limited Vasculitis;   Microscopic Polyangiitis
Interventions: Biological: Infliximab;   Drug: Cyclophosphamide;   Drug: Prednisolone;   Drug: Azathioprine;   Procedure: Plasma exchange;   Drug: Mycophenolate mofetil;   Drug: Methylprednisolone
30 Unknown  Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides
Conditions: Wegener's Granulomatosis;   Churg-Strauss Syndrome;   Microscopic Polyangiitis;   Polyarteritis Nodosa
Interventions: Drug: Methotrexate;   Drug: Cyclophosphamide
31 Completed Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides
Conditions: ANCA Associated Systemic Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis
Intervention: Drug: cyclophosphamide
32 Completed Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis;   Churg-Strauss Syndrome;   Polyarteritis Nodosa
Interventions: Drug: prednisone, methylprednisolone,cyclophosphamides;   Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;   Drug: Mycophenolate mofetil,methotrexate
33 Recruiting Vasculitis Pregnancy Registry
Conditions: Vasculitis;   Behcet's Disease;   CNS Vasculitis;   Cryoglobulinemic Vasculitis;   Eosinophilic Granulomatosis With Polyangiitis (EGPA);   Churg-Strauss Syndrome (CSS);   Granulomatosis With Polyangiitis (GPA);   Wegener's Granulomatosis;   IgA Vasculitis;   Henoch-Schoenlein Purpura (HSP);   Microscopic Polyangiitis (MPA);   Polyarteritis Nodosa (PAN);   Takayasu Arteritis (TAK);   Urticarial Vasculitis;   Systemic Vasculitis
Intervention: Other: Online questionnaires
34 Active, not recruiting The ANCA Vasculitis Questionnaire (AAV-PRO©)
Conditions: Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA);   Churg-Strauss Syndrome (CSS);   Granulomatosis With Polyangiitis (Wegener's) (GPA);   Wegener Granulomatosis (WG);   Microscopic Polyangiitis (MPA);   ANCA-Associated Vasculitis (AAV);   Vasculitis
Intervention: Other: Online questionnaire
35 Terminated IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Conditions: ANCA Associated Systemic Vasculitis Including Wegener’s;   Granulomatosis and Microscopic Polyangiitis and;   Renal Limited Vasculitis
Interventions: Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Azathioprine;   Drug: Prednisone (and methylprednisolone)
36 Recruiting A Study Evaluating the Safety and Efficacy of Ristova (Rituximab) in Combination With Glucocorticoids in Patients With Wegener's Granulomatosis or Microscopic Polyangitis
Condition: Wegener's Granulomatosis, Microscopic Polyangiitis
Interventions: Drug: methylprednisolone;   Drug: prednisone;   Drug: rituximab [Ristova]
37 Recruiting A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Condition: Granulomatosis With Polyangiitis
Intervention: Drug: Rituximab
38 Unknown  Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)
Conditions: Wegener's Granulomatosis;   Vasculitis
Interventions: Drug: mycophenolate mofetil;   Drug: cyclophosphamide
39 Active, not recruiting Belimumab in Remission of VASculitis
Condition: Vasculitis
Interventions: Biological: Placebo;   Biological: Belimumab 10 mg/kg;   Drug: Azathioprine
40 Terminated Intravenous Immunoglobulin After Relapse in Vasculitis
Conditions: ANCA + Vasculitides Relapsing Either Under Corticosteroid;   and Immunosuppressant Therapies or After One Year;   Post Treatment.
Intervention: Drug: Intravenous immunoglobulins (human immunoglobulins G)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-44) Show next page of results    Last Page
Indicates status has not been verified in more than two years